| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/23/2004 | CA2518409A1 Composition and method for treating inflammations by reducing c-reactive protein |
| 09/23/2004 | CA2518385A1 Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine |
| 09/23/2004 | CA2518357A1 Method of treating cancer with azaspirane compositions |
| 09/23/2004 | CA2518216A1 Oral insulin therapies and protocol |
| 09/23/2004 | CA2517845A1 Selective cytokine inhibitory drugs for treating disorders of the central nervous system |
| 09/23/2004 | CA2517782A1 Improved bioavailability and improved delivery of alkaline pharmaceutical drugs |
| 09/23/2004 | CA2517160A1 Method of treating and preventing hyperparathyroidism with vitamin d compounds |
| 09/22/2004 | EP1460120A1 Anion generating material and skin treating agent using the same |
| 09/22/2004 | EP1459765A1 6-fluorobicyclo 3.1.0 hexane derivatives |
| 09/22/2004 | EP1459764A1 Remedies for mild recognition deflict |
| 09/22/2004 | EP1459763A1 Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug |
| 09/22/2004 | EP1459762A1 Preventives remedies for proliferative organ diseases chronic arthritic diseases hypertrophic scar or keloid |
| 09/22/2004 | EP1459756A1 REMOVAL PROMOTERS AND INHIBITOR FOR APOPTOSIS CELLS i IN VIVO /i |
| 09/22/2004 | EP1459752A2 Bisdioxopiperazine for the treatment of accidental extravasation of anthracyclines |
| 09/22/2004 | EP1459743A2 Agent for prophylaxis and treatment of glaucoma |
| 09/22/2004 | EP1459742A2 Agent for prophylaxis and treatment of asthenopia and pseudomyopia |
| 09/22/2004 | EP1459727A1 Nonhuman model animal unresponsive to immunopotentiating synthetic compound |
| 09/22/2004 | EP1459070A2 Methods for diagnosis and treatment of epithelial-derived cancers, such as colorectal cancers and kidney cancers |
| 09/22/2004 | EP1459063A2 Screening method for compounds that modulate neuronal activity |
| 09/22/2004 | EP1458885A2 The use of histamine h4 receptor antagonist for the treatment of inflammatory response |
| 09/22/2004 | EP1458866A2 Modified tridegins, production and use thereof as transglutaminase inhibitors |
| 09/22/2004 | EP1458865A2 Human vanilloid receptor protein and polynucleotide sequence encoding same |
| 09/22/2004 | EP1458863A1 A system for stable expression of sirnas in mammalian cells |
| 09/22/2004 | EP1458858A2 Histone h3 methyltransferase polypeptide |
| 09/22/2004 | EP1458756A1 Chemokine mutants acting as chemokine antagonists |
| 09/22/2004 | EP1458754A2 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control |
| 09/22/2004 | EP1458734A1 Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
| 09/22/2004 | EP1458726A2 Mitotic kinesin inhibitors |
| 09/22/2004 | EP1458725A1 A novel sordarin derivative isolated from culture fermentations and functions as an antifungal agent |
| 09/22/2004 | EP1458722A1 Pyrrolopyrimidines as phosphodiesterase vii inhibitors |
| 09/22/2004 | EP1458719A1 Pyridoquinoxaline antivirals |
| 09/22/2004 | EP1458708A2 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| 09/22/2004 | EP1458679A2 Pyrrolidine derivatives as prostaglandin modulators |
| 09/22/2004 | EP1458677A1 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha |
| 09/22/2004 | EP1458673A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) |
| 09/22/2004 | EP1458672A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha(ppar) |
| 09/22/2004 | EP1458447A2 Combination of cytochome p 450 dependent protease inhibitors |
| 09/22/2004 | EP1458427A2 Compositions comprising collagen and metalloprotease inhibitors |
| 09/22/2004 | EP1458413A2 Pharmaceutical compositions based on azetidine derivatives |
| 09/22/2004 | EP1458412A1 Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 09/22/2004 | EP1458401A1 Composition comprising dextrinsulfate for the treatment of sexual transmitted diseases (std) |
| 09/22/2004 | EP1458400A1 Liquid bisphosphonate formulations for bone disorders |
| 09/22/2004 | EP1458399A1 Pregnane steroids for use in the treatment of cns disorders |
| 09/22/2004 | EP1458398A1 Antibiotic formulation and a method of making this formulation |
| 09/22/2004 | EP1458397A1 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
| 09/22/2004 | EP1458392A2 Acridone inhibitors of impdh enzyme |
| 09/22/2004 | EP1458385A2 Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 |
| 09/22/2004 | EP1458383A2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| 09/22/2004 | EP1458382A1 Amide derivatives as gk activators |
| 09/22/2004 | EP1458379A1 Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 09/22/2004 | EP1458375A2 Compositions for decreasing activity of hormone-sensitive lipase |
| 09/22/2004 | EP1458374A2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| 09/22/2004 | EP1458373A1 Use of lipoxin analogs to promote cell defense against gram-negative infections |
| 09/22/2004 | EP1458368A1 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure |
| 09/22/2004 | EP1458367A1 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| 09/22/2004 | EP1458353A1 Formulation dosage form for the controlled delivery of ther apeutic agents |
| 09/22/2004 | EP1458352A1 Solid dose micro implant |
| 09/22/2004 | EP1458349A1 Composition comprising at least an oxazolin for inhibiting langerhans cell migration, and uses thereof |
| 09/22/2004 | EP1458337A1 Stable surfactant compositions for suspending components |
| 09/22/2004 | EP1458234A1 Disruption of the prostaglandin e synthase 2 gene |
| 09/22/2004 | EP1350104A4 Presenilin enhancers |
| 09/22/2004 | EP1272154B1 Composition for improving skin lipid barrier function |
| 09/22/2004 | EP1261335A4 Brain, spinal and nerve injury treatment |
| 09/22/2004 | EP1259598B1 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 09/22/2004 | EP1235925A4 Feeding assay for identifying nematicidal compounds |
| 09/22/2004 | EP1173766B1 A tenascin-c isoform as a marker for neoplasias |
| 09/22/2004 | EP1146874B1 Vitronectin receptor antagonist |
| 09/22/2004 | EP1141251A4 Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders |
| 09/22/2004 | EP1135161B1 Chemotherapeutic composition and method |
| 09/22/2004 | EP1100781B1 High affinity ligands for nociceptin receptor orl-1 |
| 09/22/2004 | EP1096955B1 Uses of antibodies to aminophospholipids for cancer treatment |
| 09/22/2004 | EP1093455B1 Bis-indole derivatives and their use as antiinflammatory agents |
| 09/22/2004 | EP1060174B1 Nitric oxide releasing chelating agents and their therapeutic use |
| 09/22/2004 | EP0841900B1 Pharmaceutical composition for detecting lung disease |
| 09/22/2004 | EP0831767B1 Alpha hydroxyacid esters for skin aging |
| 09/22/2004 | EP0768895B1 Camptothecin drug combinations and medicaments with reduced side effects |
| 09/22/2004 | CN1531554A Humanized antibodies derived from DD-3B6-22, specific for D-dimer fragment of fibrin |
| 09/22/2004 | CN1531545A Reducing immunogenicity of fusion proteins |
| 09/22/2004 | CN1531535A Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 09/22/2004 | CN1531441A Pharmaceutical compositinos which inhibit vascular proliferation and method of use thereof |
| 09/22/2004 | CN1531440A Pharmaceutical composition for preventing or treating TH1 and TH2 cell related diseases by modulating TH/TH2 ratio |
| 09/22/2004 | CN1531438A Normalization of defective T cell responsiveness through manipulation of thymic regeneration |
| 09/22/2004 | CN1531437A Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by body |
| 09/22/2004 | CN1531434A Selective dopamine D4 receptor agonists for treating sexual dysfuction |
| 09/22/2004 | CN1531433A Synergistic pharmaceutical combination for prevention or treatment of diabetes |
| 09/22/2004 | CN1531431A Prevention of addiction in pain management |
| 09/22/2004 | CN1531430A Local used composition containing antifungal agent |
| 09/22/2004 | CN1531429A Medicament, containing effector of glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy |
| 09/22/2004 | CN1531421A Liquid pharaceutical for oral delivery |
| 09/22/2004 | CN1530140A Vermis expelling resinate and its preparation |
| 09/22/2004 | CN1530106A Medicine composition for treating diabet mellitus |
| 09/22/2004 | CN1530105A Medicine composition for treating diabets and mellitus |
| 09/22/2004 | CN1530102A Medical preparation containing alpha-thioctan, ambroxol and/or ACE inhibiting agent and its use in treating neurodegenerative diseases |
| 09/22/2004 | CN1530096A Powder injection containing nonsteroidal anti-infecting chemical |
| 09/22/2004 | CN1167793C Polypeptides encoded by human lipase-like gene, compositions and methods |
| 09/22/2004 | CN1167667C Aminobenzophenones as inhibitors IL-1 beta and TNF-alpha |
| 09/22/2004 | CN1167416C Use of glucose uptake enhancer for reducing post-ischemic injury of heart |
| 09/22/2004 | CN1167413C Aerosol ointment compositions and preparation thereof |
| 09/21/2004 | US6795776 Crystallographic structure of the androgen receptor ligand binding domain |
| 09/21/2004 | US6794412 Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |